Meeting
2018 ASCO Annual Meeting
Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): Results for 2nd-line therapy.
Authors
Daniel Khalaf
British Columbia Cancer Agency - Vancouver Centre, Vancouver, BC, Canada
Daniel Khalaf , Matti Annala , Daygen L. Finch , Conrad D. Oja , Joanna Vergidis , Muhammad Zulfiqar , Katherine Sunderland , Kevin Beja , Gillian Rae Vandekerkhove , Martin Gleave , Alexander William Wyatt , Kim N. Chi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02125357
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5015)
DOI
10.1200/JCO.2018.36.15_suppl.5015
Abstract #
5015
Poster Bd #
242
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.
First Author: Daniel J Khalaf
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: David Johnson Einstein
Poster
2021 Genitourinary Cancers Symposium
ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
First Author: Louise Emmett
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel P. Petrylak